黑色素瘤中B细胞与抗体反应的表型、功能、预后及预测意义:范围综述
本范围综述遵循PRISMA-ScR指南,检索三个数据库2000年至2024年的英文全文研究,最终纳入80项研究,评估黑色素瘤患者中B细胞和抗体的表型、功能及预后预测价值。研究发现肿瘤内类转换B细胞丰富、记忆B细胞密度高及免疫活性抗体同种型与更佳生存和ICI反应相关,而调节性B细胞和抗炎性IgG4同种型与不良结局相关,自身抗体产生增加与irAEs发生相关。
要点
- 肿瘤内记忆B细胞丰富及类转换B细胞浸润与更佳生存结局相关
- B细胞丰度、BCR多样性和免疫球蛋白基因重排等B细胞特征与更好ICI反应相关
- IgG4同种型抗体失调与较差结局相关,而IgG1类转换与更好临床结局和ICI反应相关
核心结论
- 类转换B细胞和免疫活性抗体同种型提示增强的经典免疫,与改善的免疫治疗反应相关。
- 替代激活的调节性B细胞和免疫惰性抗体同种型与免疫抑制及较差临床结局相关。
- 体液免疫特征有望成为预测免疫治疗反应和irAEs的生物标志物。
研究设计与样本
- 遵循PRISMA-ScR报告指南的范围综述,注册号PROSPERO CRD42024592965。
- 检索PubMed(n=827)、Scopus(n=2759)和Ovid MEDLINE(n=1081),时间范围为2000年1月1日至2024年10月9日,限英文全文。
- 初始识别4667项研究,去除1659项 duplicates 后筛选3008篇标题摘要,最终纳入80项研究。
主要发现
- 血液中初始B细胞、替代激活B细胞和调节性B细胞增多,肿瘤中偏向分化和类转换B细胞浸润。
- 肿瘤中B细胞密度(尤其记忆B细胞丰度)与更有利的生存结局一致相关。
- 肿瘤中B细胞丰度、B细胞受体多样性和免疫球蛋白基因重排等B细胞特征与更好ICI反应相关。
- 抗炎性IgG4同种型抗体失调与较差结局相关,而向免疫刺激性同种型(如IgG1)类转换与更好临床结局和ICI反应相关。
- 抗体反应性和自身抗体分析显示患者存在独特同种型特征、癌症抗原反应性抗体,以及ICI治疗中自身抗体产生增加与irAEs发生相关。
临床怎么用
- 肿瘤内记忆B细胞密度和类转换B细胞浸润可能作为预后标志物辅助风险评估。
- B细胞受体多样性、免疫球蛋白基因重排和抗体同种型特征可能用于预测ICI反应。
- 治疗中自身抗体产生增加可能提示irAEs风险,需加强监测。
局限性
- 肿瘤和免疫反应存在异质性,可能影响结果的普适性。
- 纳入研究为英文全文,可能遗漏非英文发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical significance of B cells and the antibodies they express is increasingly appreciated in melanoma, a highly immunogenic tumour, for which immune checkpoint inhibitor (ICI) therapy is the standard care for advanced disease. OBJECTIVES: To evaluate the phenotypes and roles of B cells and antibodies in patients with melanoma, and their prognostic and predictive value, in a scoping review following PRISMA-ScR reporting guidelines. METHODS: Using three search engines, we conducted literature searches for full-text studies written in English from 1 January 2000 to 9 October 2024. Three reviewers conducted title and abstract screening, followed by full-text paper assessment by two independent reviewers. This study was registered with PROSPERO (CRD42024592965). RESULTS: Of 4667 identified studies (PubMed, n = 827; Scopus, n = 2759; Ovid MEDLINE, n = 1081), 1659 were duplicates. The titles and abstracts of the remaining 3008 were screened to yield 251 full-text papers, resulting in the inclusion of 80 studies. Our search identified increased naïve, alternatively activated and regulatory B cells in blood, and a bias towards differentiated and class-switched B-cell infiltrates in tumours. Consistent associations were found between B-cell density in tumours, particularly the abundance of memory B cells and more favourable survival outcomes. Despite tumour and immune response heterogeneity, collectively, enriched B-cell signatures such as B-cell abundance, B-cell receptor diversity and immunoglobulin gene rearrangement in tumours correlated with better ICI response. Antibody dysregulation favouring the anti-inflammatory IgG4 isotype was associated with less-favourable outcomes, while class switching to immune-stimulating isotypes such as IgG1 correlated with better clinical outcomes and ICI response. Antibody reactivity and autoantibody analysis revealed distinct isotype signatures in patients, the presence of cancer antigen-reactive antibodies and an association between increased autoantibody production on treatment with ICIs and the development of toxicity (immune-related adverse events; irAEs). CONCLUSIONS: We draw consensus for associations between class-switched B cells and immune-active antibody isotypes that indicate heightened classical immunity, with improved immunotherapy response. Alternatively activated, regulatory B cells and immune-inert antibody isotypes are associated with immunosuppression and less-favourable clinical outcomes. We reveal aspects of humoral immunity that offer opportunities to identify predictive biomarkers of immunotherapy response and irAEs. Melanoma is the deadliest type of skin cancer. It is becoming more common, with around 325,000 new cases diagnosed every year worldwide. Immunotherapy is a treatment option that activates a person’s immune system to fight cancer. Immunotherapy has already greatly improved survival for patients with melanoma. Unfortunately, only half of patients benefit from immunotherapy. Some people also stop treatment early due to bad side effects. In this study, we did an organized and systematic search of the existing evidence on melanoma. This is called a ‘scoping review’. We did this to study the role of immune cells called ‘B cells’ and the antibodies they produce. Antibodies are proteins that circulate in the body. They protect against things like bacteria and viruses. We found that people with melanoma have different types of B cells and antibodies in their blood than people who do not have melanoma. Inside melanoma tumours and in the blood, the presence of more mature B cells was linked to better survival of people with melanoma. People whose B cells were better able to stimulate the immune system benefitted more from immunotherapy. But, the presence of other types of B cells and antibodies was linked to harmful side effects from treatment and poorer survival. B cells and their antibodies have positive and negative roles in how a person with melanoma responds to immunotherapy. A better understanding of this could help predict who will benefit most from treatment. This will allow doctors to help counteract harmful side effects.
引用
- Booth L, Chen X, Stoker K, et al. Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review. Br J Dermatol. 2026. PMID: 41742701. doi:10.1093/bjd/ljag074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。